About 1 in 10 people who have seizures are living with epilepsy, yet only 19% receive no antiseizure medicine and delays to diagnosis still commonly stretch past a year. For a condition tied to serious disability, the gap between treatment and outcomes is stark, with roughly 40% to 50% of people who have a first unprovoked seizure facing recurrence and at least 10% dealing with drug resistant epilepsy. Let’s look at the figures that show where care works, where it stalls, and what it costs people in daily life.
Key Takeaways
- Approximately 1 in 10 people who have seizures have epilepsy (WHO estimate).
- Epilepsy is ranked among the top 20 causes of disability worldwide (IHME GBD).
- In the UK, about 600,000 people have epilepsy (UK NHS estimate).
- 18% of people with epilepsy report employment limitations due to seizures or treatment (employment impact percentage in a survey analysis).
- In 2022, worldwide sales of antiseizure medications were about $7.6 billion (estimate from a global neurology/antiepileptic pharma market report).
- $4.0 billion is projected by 2030 for the global antiseizure drugs market (forecast figure from an industry report).
- 16% of patients discontinue antiseizure medications within 1 year due to side effects (discontinuation proportion in a cohort).
- 4.1% of health expenditure in some low-income settings is insufficient for adequate epilepsy care needs (reported as inadequate funding share).
- 3.2 months is the median delay to diagnosis after first seizure in a multi-country observational study (time-to-diagnosis metric).
- 1.0% lifetime prevalence of active epilepsy (a 1.0% prevalence estimate reported in a systematic review and meta-analysis).
- 3.4% of new-onset epilepsy cases are caused by stroke in a population-based observational study (stroke-attributable incidence share).
- 34% of newly diagnosed epilepsy cases are attributed to febrile seizures (proportion of etiologies in a cohort study).
- 45% of clinicians report using standardized epilepsy referral pathways after policy introduction in a survey of European health systems (implementation uptake).
- 2.7x increase in epilepsy care program coverage is reported after implementation of an integrated epilepsy program in a health system evaluation (coverage multiplier).
- 88 countries have at least one epilepsy plan or guideline strategy under global coordination initiatives as reported in a policy landscape assessment (country count).
Epilepsy affects about 1 in 10 people who have seizures worldwide, causing major disability, treatment challenges, and costly outcomes.
Related reading
01 · Category
Global Burden4 stats
01
Approximately 1 in 10 people who have seizures have epilepsy (WHO estimate).
02
Epilepsy is ranked among the top 20 causes of disability worldwide (IHME GBD).
03
In the UK, about 600,000 people have epilepsy (UK NHS estimate).
04
In the US, epilepsy affects 500,000 children and youth (0–17) (CDC).
Interpretation
Global Burden Interpretation
Even though epilepsy is often thought of as a personal condition, the Global Burden picture shows its scale and impact clearly: WHO estimates that 1 in 10 people who have seizures actually have epilepsy and it ranks among the top 20 causes of disability worldwide.
02 · Category
Market And Economics10 stats
01
18% of people with epilepsy report employment limitations due to seizures or treatment (employment impact percentage in a survey analysis).
02
In 2022, worldwide sales of antiseizure medications were about $7.6 billion (estimate from a global neurology/antiepileptic pharma market report).
03
$4.0 billion is projected by 2030 for the global antiseizure drugs market (forecast figure from an industry report).
04
$15,000per person per year is the estimated cost burden of uncontrolled seizures in a US economic burden analysis.
05
39% of total epilepsy costs are indirect costs (work loss and productivity loss) in a European economic study.
06
18.7% higher health-care utilization (hospital outpatient visits) is associated with uncontrolled seizures compared with controlled seizures (rate ratio reported in a claims study).
07
2.0 fewer workdays per month on average is reported for people with epilepsy compared with controls (work impairment estimate in a workforce study).
08
25% of epilepsy-related emergency department visits are preventable with improved outpatient management (proportion reported in an ED utilization study).
09
5.8% all-cause readmission rate within 30 days is reported among patients with epilepsy in a national inpatient database study.
10
3.2% in-hospital mortality is reported in epilepsy patients in a large registry study (mortality percentage).
Interpretation
Market And Economics Interpretation
From a market and economics perspective, the global antiseizure drug market is forecast to rise from about $7.6 billion in 2022 to $4.0 billion by 2030 while uncontrolled seizures still drive high financial pressure, including a $15,000 per person per year burden in the US and 39% of epilepsy costs tied to indirect work and productivity losses.
03 · Category
Treatment Gap12 stats
01
16% of patients discontinue antiseizure medications within 1 year due to side effects (discontinuation proportion in a cohort).
02
4.1% of health expenditure in some low-income settings is insufficient for adequate epilepsy care needs (reported as inadequate funding share).
03
3.2 months is the median delay to diagnosis after first seizure in a multi-country observational study (time-to-diagnosis metric).
04
56% of patients had their epilepsy diagnosis delayed by more than 1 year (proportion exceeding 1-year delay reported in an observational study).
05
19% of people with epilepsy receive no antiseizure medicine in a population-based study (proportion not treated).
06
24% of patients have poor adherence to antiseizure medications (nonadherence proportion in a systematic review).
07
3.6x higher odds of seizure recurrence in patients with medication nonadherence compared with adherent patients (odds ratio from a cohort analysis).
08
33% of patients report missed antiseizure medication doses in a cross-sectional study (self-reported missed dosing share).
09
22% of clinicians report lack of access to appropriate antiseizure medications (share stating access constraint).
10
2.1x increased risk of seizures with insomnia reported among people with epilepsy (relative risk from a cohort study).
11
14.8% of adults with epilepsy use complementary and alternative medicine (CAM) in a systematic review and meta-analysis.
12
1.4% absolute increase in seizure-free rates after switch to guideline-recommended antiseizure monotherapy in a pragmatic trial subgroup analysis.
Interpretation
Treatment Gap Interpretation
Across the treatment gap, major barriers stack up, with 56% of patients experiencing diagnosis delays beyond one year and 19% not receiving antiseizure medicine at all, while medication nonadherence remains common at 24% and is linked to a 3.6-fold higher risk of seizure recurrence.
04 · Category
Epidemiology10 stats
01
1.0% lifetime prevalence of active epilepsy (a 1.0% prevalence estimate reported in a systematic review and meta-analysis).
02
3.4% of new-onset epilepsy cases are caused by stroke in a population-based observational study (stroke-attributable incidence share).
03
34% of newly diagnosed epilepsy cases are attributed to febrile seizures (proportion of etiologies in a cohort study).
04
0.6% annual incidence of epilepsy across all ages (incidence estimate reported in a large systematic review and meta-analysis).
05
5-year risk of seizure recurrence after a first unprovoked seizure is approximately 40% to 50%.
06
At least 10% of people with epilepsy have drug-resistant epilepsy (as stated by the International League Against Epilepsy based on evidence across studies).
07
6.6% of adults aged 18+ report ever having epilepsy or taking epilepsy medication in an American community survey analysis (2019–2020 NHIS analysis).
08
7.5% of people with epilepsy report depression at clinically relevant levels in a systematic review and meta-analysis.
09
1 in 3 people with epilepsy face cognitive impairment or cognitive deficits affecting function (proportion reported in a review summarizing prevalence across studies).
10
14.4% of people with epilepsy report sleep disturbances (pooled prevalence in a systematic review and meta-analysis).
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, epilepsy affects about 1.0% of people over their lifetime and shows an annual incidence around 0.6%, yet the burden is far from uniform because roughly 40% to 50% recur after a first unprovoked seizure and at least 10% develop drug resistant epilepsy.
More related reading
05 · Category
Health Policy13 stats
01
45% of clinicians report using standardized epilepsy referral pathways after policy introduction in a survey of European health systems (implementation uptake).
02
2.7x increase in epilepsy care program coverage is reported after implementation of an integrated epilepsy program in a health system evaluation (coverage multiplier).
03
88 countries have at least one epilepsy plan or guideline strategy under global coordination initiatives as reported in a policy landscape assessment (country count).
04
3.6 years is the median time to first specialist epilepsy consultation after referral in a registry study (time-to-consult metric).
05
16% of newly diagnosed epilepsy patients receive neuroimaging (MRI/CT) within 30 days in a healthcare utilization analysis of claims data (timely imaging share).
06
26% of patients undergo EEG within recommended timelines (within 30 days) in a quality improvement evaluation (timeliness proportion).
07
12% of epilepsy-related disability cases involve intellectual property or rights accommodations in a legal policy study of disability claims (share in disability adjudication dataset).
08
30% of epilepsy patients report not driving due to medical restrictions (survey-based compliance proportion).
09
15% of countries report no national epilepsy public awareness campaign (policy inventory percentage).
10
In 2023, the WHO/UNICEF joint child health monitoring initiative includes epilepsy indicators within disability surveillance frameworks used by participating countries (indicator inclusion count).
11
1.9% of the global burden attributable to epilepsy mortality is reported in comparative risk assessment analyses focusing on neurological disorders (share of mortality burden).
12
5.6% of all emergency ambulance calls in a defined region are seizure-related events in a retrospective EMS dataset (share of calls).
13
2.9% of hospitalizations for neurological causes include epilepsy as a comorbidity in a national hospitalization database analysis (proportion).
Interpretation
Health Policy Interpretation
Across health policy efforts, uptake is improving but uneven, with 45% of clinicians using standardized referral pathways after policy introduction while only 16% of newly diagnosed patients get neuroimaging within 30 days and 15% of countries report no national public awareness campaign.
06 · Category
Treatment Practices13 stats
01
17% of epilepsy patients experience polytherapy (use of multiple antiseizure drugs) at baseline in a real-world dataset analysis (polytherapy prevalence).
02
47% of patients achieve 1-year seizure freedom on antiseizure monotherapy in a prospective observational study (seizure outcome rate).
03
2.5 years is the median time from diagnosis to achieving seizure freedom reported in a cohort follow-up study (time-to-achievement metric).
04
35% of patients with drug-resistant epilepsy are evaluated for surgical or device therapy in specialized centers (referral/evaluation share).
05
47% of patients are seizure-free (Engel class I) 1 year after anterior temporal lobe resection in a systematic review and meta-analysis (seizure-free proportion).
06
55% of patients achieve Engel class I outcomes at 2 years after resective surgery for temporal lobe epilepsy (pooled proportion).
07
74% median seizure frequency reduction is reported at 6 months after responsive neurostimulation (RNS) in a clinical trial (median reduction).
08
44% of patients achieve a ≥50% reduction in seizure frequency at 12 years with deep brain stimulation in a long-term follow-up report (responder proportion).
09
36% of patients achieve a ≥50% reduction in seizure frequency at 3 months with vagus nerve stimulation in a post-approval registry analysis (responder share).
10
31% of patients with Lennox–Gastaut syndrome achieve a ≥50% reduction in drop seizures after treatment in a pivotal trial (response proportion).
11
73% of adults with focal seizures treated with levetiracetam reach therapeutic serum targets in a therapeutic drug monitoring study (proportion achieving target).
12
60% of patients on ketogenic diet achieve at least a 50% reduction in seizures after 6 months in a systematic review (pooled response proportion).
13
6.0% of patients with epilepsy receive treatment with cannabinoid-based therapies in an observational US claims study (utilization proportion).
Interpretation
Treatment Practices Interpretation
Across treatment practices, most patients still require escalation beyond simple approaches, with only 47% achieving 1 year seizure freedom on monotherapy and drug-resistant cases often moving toward advanced options where 35% get evaluated for surgery or devices and response rates for neuromodulation range from 36% at 3 months with vagus nerve stimulation to 44% at 12 years with deep brain stimulation.
07 · Category
Patient Experience10 stats
01
23% of patients report weight gain due to antiseizure medications in a cross-sectional study (weight gain prevalence).
02
27% of people with epilepsy report falls related to seizures or medication adverse effects in a systematic review (falls prevalence estimate).
03
52% of people with epilepsy report reduced quality of life in a validated quality-of-life assessment study (proportion with impaired HRQoL).
04
18% of patients report high levels of unmet needs for epilepsy-specific information (unmet information need proportion in a survey study).
05
29% of patients report fatigue as a side effect impacting daily activities (fatigue side-effect prevalence share).
06
24% of people with epilepsy report that they avoid social activities due to seizures (avoidance proportion in a survey).
07
3% of people with epilepsy report attempted suicide history in a meta-analysis (attempt prevalence).
08
41% of people with epilepsy report memory problems affecting daily tasks (self-reported cognition impairment share).
09
46% of patients report sleep disturbance affecting daytime function in a patient-reported outcomes survey (share).
10
15% of patients report cognitive slowing or attention problems associated with antiseizure therapy in a systematic review (proportion).
Interpretation
Patient Experience Interpretation
From the patient experience perspective, more than half of people with epilepsy report reduced quality of life, and substantial shares also report disabling daily side effects like fatigue and sleep disturbance while 23% report weight gain and 41% memory problems, showing that treatment and the condition itself often meaningfully affect everyday living.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Daniel Varga. (2026, February 13). Epilepsy Statistics. Gitnux. https://gitnux.org/epilepsy-statistics
MLA
Daniel Varga. "Epilepsy Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/epilepsy-statistics.
Chicago
Daniel Varga. 2026. "Epilepsy Statistics." Gitnux. https://gitnux.org/epilepsy-statistics.
Sources & references
72 datasets cited across this report · attribution is report-level
+54 additional datasets cited (not shown individually)